Læknablaðið - nóv. 2018, Blaðsíða 17

LÆKNAblaðið 2018/104 497
R A N N S Ó K N
Einar Logi Snorrason
Bergrós Kristín Jóhannesdóttir
Thor Aspelund
Vilmundur Gudnason
Karl Andersen
Introduction: Despite the decreasing incidence rate of acute
coronary syndromes worldwide, the incidence of NSTEMI (Non-
ST elevation myocardial infarction) has increased relative to
STEMI (ST elevation myocardial infarction). The aim of this study
was to compare long-term survival rates of NSTEMI and STEMI
patients and to explore the effects of risk factors on survival.
Material and methods: All patients hospitaized for acute
myocardial infarction at Landspitali University Hospital during
the calendar year of 2006 were included in the study. Information
about risk factors was obtained using electronic medical records.
The primary endpoint was all cause mortality, the secondary end-
point was defined as death or myocardial infartion. Patients were
followed up to January 1st 2015.
Results: Among 447 patients diagnosed with acute myocardial
infarction in Iceland in 2006, 280 patients were diagnosed with
NSTEMI (I21.4) and 167 with STEMI (I21, I21.9). NSTEMI and
STEMI incidence rates per 100.000 inhabitants in Iceland were
91.3 and 55.9, respectively. The mean age of NSTEMI patients
was 73.0 years, women were on average 8.4 years older than
men. The mean age of STEMI patients was 65.3 years, women
were on average 7.3 years older than men. The five-year survi-
val rate for NSTEMI patients was 51%, 42% among women and
57% among men. The five-year survival rate for STEMI patients
was 77%, 68% among women and 80% among men. Five year
age-adjusted survival rates were higher for STEMI than NSTEMI
(logrank: p <0.01).
Conclusion: The incidence of NSTEMI was higher than that of
STEMI in Iceland in 2006. The worse prognosis of women as
compared to men was due to the higher mean age of women.
Overall, long-term survival of NSTEMI patients was worse than
that of STEMI patients even after adjustment for difference in
age.
Long-term survival of patients with acute myocardial infarction in Iceland
ENGLISH SUMMARY
Key words: acute myocardial infarction, prognosis, long term survival, ST elevation myocardial infarction, Non ST elevation myocardial infarction.
Correspondence: Karl Andersen, andersen@landspitali.is
1. Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P,
Leon DA. Contributions of risk factors and medical care to
cardiovascular mortality trends. Nat Rev Cardiol 2015;12:
508­30.
2. Laslett LJ, Alagona PJ, Clark BA 3rd, Drozda JPJ, Saldivar
F, Wilson SR, et al. The worldwide environment of
cardiovascular disease: prevalence, diagnosis, therapy,
and policy issues: a report from the American College of
Cardiology. J Am Coll Cardiol 2012; 60(25 Suppl): S1­49.
3. WHO | Cardiovascular diseases (CVDs). WHO ­ 2017.
4. Nichols M, Townsend N, Scarborough P, Rayner M.
Cardiovascular disease in Europe 2014: epidemiological
update. Eur Heart J 2014; 35: 2950­9.
5. Andersen K, Aspelund T, Guðmundsson EF, Siggeirsdóttir
K, Þórólfsdóttir RB, Sigurðsson G, et al. Yfirlitsgrein. Úr
gögnum Hjartaverndar: Faraldsfræði kransæðasjúkdóma
á Íslandi í hálfa öld Læknablaðið 2017; 103: 411­20.
6. Andersen K, Jóhannesdóttir BK, Kristjánsson JM,
Gudnason T. Decreasing case fatality in myocardial
infarction is explained by improved medical treatment.
Acta Cardiol 2011; 66: 39­46.
7. Aspelund T, Gudnason V, Magnusdottir BT, Andersen
K, Sigurdsson G, Thorsson B, et al. Analysing the large
decline in coronary heart disease mortality in the icelandic
population aged 25­74 between the years 1981 and 2006.
PLoS One. 2010; 5: 1­8.
8. Yeh RW, Sidney S, Chandra M, Sorel M, Selby J V, Go AS.
Population trends in the incidence and outcomes of acute
myocardial infarction. N Engl J Med 2010; 362: 2155­65.
9. Terkelsen CJ, Lassen JF, Norgaard BL, Gerdes JC, Jensen
T, Gotzsche LB­H, et al. Mortality rates in patients with
ST­elevation vs. non­ST­elevation acute myocardial
infarction: observations from an unselected cohort. Eur
Heart J 2005; 26: 18­26.
10. Taneja AK, Collinson J, Flather MD, Bakhai A, de Arenaza
DP, Wang D, et al. Mortality following non­ST elevation
acute coronary syndrome: 4 years follow­up of the PRAIS
UK Registry (Prospective Registry of Acute Ischaemic
Syndromes in the UK). Eur Heart J 2004; 25: 2013­8.
11. Vagnarelli F, Taglieri N, Ortolani P, Norscini G, Cinti
L, Bacchi Reggiani ML, et al. Long­Term Outcomes and
Causes of Death After Acute Coronary Syndrome in
Patients in the Bologna, Italy, Area. Am J Cardiol 2018; 115:
171­7.
12. Pilgrim T, Vranckx P, Valgimigli M, Stefanini GG, Piccolo
R, Rat J, et al .Risk and timing of recurrent ischemic
events among patients with stable ischemic heart disea­
se, non­ST­segment elevation acute coronary syndrome,
and ST­segment elevation myocardialinfarction. Am Heart
J 2016; 175: 56­65.
13. Roffi M, Patrono C, Collet J­P, Mueller C, Valgimigli
M, Andreotti F, et al. 2015 ESC Guidelines for the
management of acute coronary syndromes in patients
presenting without persistent ST­segment elevation: Task
Force for the Management of Acute Coronary Syndromes
in Patients Presenting without Persistent ST­Segment
Elevation of th. Eur Heart J 2016; 37: 267­315.
14. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli­
Ducci C, Bueno H, et al. 2017 ESC Guidelines for the
management of acute myocardial infarction in patients
presenting with ST­segment elevation: The Task Force for
the management of acute myocardial infarction in patients
presenting with ST­segment elevation of the European
Society. Eur Heart J 2018; 39: 119­77.
15. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J,
Aaberge L, et al. Reperfusion therapy for ST elevation
acute myocardial infarction in Europe: description of the
current situation in 30 countries. Eur Heart J 2010; 31: 943­
57.
16. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D,
Goldberg RJ. Recent trends in the incidence, treatment,
and outcomes of patients with STEMI and NSTEMI. Am J
Med 2011; 124: 40­7.
17. van Leeuwen MAH, Daemen J, van Mieghem NM, de Boer
SPM, Boersma E, van Geuns RJ, et al. Comparison of long­
term outcomes in STEMI and NSTE­ACS after coronary
stent placement: an analysis in a real world BMS and DES
population. Int J Cardiol 2018; 167: 2082­7.
18. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB,
Betriu A, et al. Acute coronary syndromes in the GUSTO­
IIb trial: prognostic insights and impact of recurrent
ischemia. The GUSTO­IIb Investigators. Circulation 1998;
98: 1860­8.
19. Sulo G, Vollset SE, Nygard O, Igland J, Egeland GM,
Ebbing M, et al. Trends in acute myocardial infarction
event rates and risk of recurrences after an incident event
in Norway 1994 to 2009 (from a Cardiovascular Disease in
Norway Project). Am J Cardiol 2014; 113:­1777–81.

20. Wagner A, Arveiler D, Ruidavets JB, Bingham A, Montaye
M, Ferrieres J, et al. Gender­ and age­specific trends in
coronary heart disease mortality in France from 2000
to 2007: results from the MONICA registers. Eur J Prev
Cardiol 2014; 21: 117­22.
21. Huxley R, Barzi F, Woodward M. Excess risk of fatal
coronary heart disease associated with diabetes in men
and women: meta­analysis of 37 prospective cohort stu­
dies. BMJ Br Med J 2006; 332: 73­8.
22. Hulley S, Grady D, Bush T, Furberg C, Herrington D,
Riggs B, et al. Randomized trial of estrogen plus progestin
for secondary prevention of coronary heart disease in
postmenopausal women. Heart and Estrogen/progestin
Replacement Study (HERS) Research Group. JAMA 1998;
280: 605­13.
23. Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S,
Battler A, et al. Age, clinical presentation, and outcome
of acute coronary syndromes in the Euroheart acute
coronary syndrome survey. Eur Heart J 2006; 27: 789­95.
24. Gupta T, Kolte D, Khera S, Harikrishnan P, Mujib M,
Aronow WS, et al. Smoker's Paradox in Patients With
ST­Segment Elevation Myocardial Infarction Undergoing
Primary Percutaneous Coronary Intervention. J Am Heart
Assoc 2016; 5.
25. Gennaro G, Brener SJ, Redfors B, Kirtane AJ, Généreux
P, Maehara A, et al. Effect of Smoking on Infarct Size and
Major Adverse Cardiac Events in Patients With Large
Anterior ST­Elevation Myocardial Infarction (from the
INFUSE­AMI Trial). Am J Cardiol 2016; 118: 1097­104.
26. Galkina E, Ley K. Immune and Inflammatory Mechanisms
of Atherosclerosis. Annu Rev Immunol 2009; 27: 165­97.
27. Vogel B, Hahne S, Kozanli I, Kalla K, Jarai R, Freynhofer
M, et al. Influence of updated guidelines on short­ and
long­term mortality in patients with non­ST­segment
elevation acute coronary syndrome (NSTE­ACS). Int J
Cardiol 2018; 159: 198­204.
Heimildir
Barst til blaðsins 5. maí 2018,
samþykkt til birtingar 21. október 2018.